MDVN - Medivation, Inc.

Medivation, Inc. (MDVN) was a biopharmaceutical company focused on developing novel therapies for the treatment of serious diseases, including cancer and neurological disorders. In September 2016, the company was acquired by Pfizer Inc.

At the time of the acquisition, Medivation had one marketed product, XTANDI (enzalutamide), which was approved by the US Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer. The company was also developing several other product candidates, including pidilizumab for the treatment of diffuse large B-cell lymphoma and talazoparib for the treatment of BRCA-mutated breast and ovarian cancers.

Medivation's strategic focus was on developing innovative therapies that target specific molecular pathways involved in the development and progression of cancer and other diseases. The company used a combination of in-house research and development, as well as collaborations and partnerships with academic institutions and other biopharmaceutical companies, to advance its product pipeline.

In terms of financial performance, Medivation reported revenue of $2.2 billion for the full year 2015, compared to revenue of $943 million in the previous year. The company reported net income of $515 million for the full year 2015, compared to a net loss of $249 million in the previous year.

Overall, Medivation was a biopharmaceutical company focused on developing novel therapies for the treatment of serious diseases, including cancer and neurological disorders. The company's acquisition by Pfizer in 2016 reflects the growing interest in the development of targeted therapies for cancer and other diseases, and underscores the importance of innovation and collaboration in the biopharmaceutical industry.